Bilirubin Meters Market Report 2026

The bilirubin meters market size has grown strongly in recent years. It will grow from $0.57 billion in 2025 to $0.61 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing prevalence of neonatal jaundice, expansion of hospital diagnostic infrastructure, adoption of laboratory-based bilirubin testing, growing awareness of liver-related disorders, improvements in optical sensing technologies.

The bilirubin meters market size is expected to see strong growth in the next few years. It will grow to $0.81 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing demand for home-based monitoring devices, rising adoption of connected diagnostic equipment, expansion of neonatal screening programs, growing use of digital diagnostics platforms, technological advancements in non-invasive measurement accuracy. Major trends in the forecast period include increasing adoption of non-invasive transcutaneous devices, rising demand for portable and handheld meters, growing integration with digital health records, expansion of point-of-care testing solutions, enhanced focus on neonatal care applications.

The growing incidence of liver diseases is anticipated to fuel expansion in the bilirubin meter market. Liver diseases encompass a wide array of disorders that compromise liver function, typically featuring inflammation, scarring, or injury from causes such as infections, toxins, genetic conditions, or ongoing illnesses. These diseases are on the rise due to escalating risk factors like obesity, heavy alcohol use, viral infections, and lifestyle-associated issues, along with enhanced diagnostic tools. Bilirubin meters play a key role in liver disease management by providing precise, non-invasive bilirubin measurements, aiding in the diagnosis, tracking, and treatment of liver impairment and jaundice. For instance, in April 2024, the UK’s Office for Health Improvement and Disparities (OHID), a government unit under the Department of Health and Social Care, reported that hospital admissions for liver disease are steadily increasing. In the financial year ending 2023, the rate climbed to 155.2 (152.9 to 157.5) per 100,000 population, up from 150.6 (148.2 to 152.9) the prior year. Thus, the rising prevalence of liver diseases is propelling the bilirubin meter market forward.

Major companies in the bilirubin meters market are pursuing strategic partnerships to improve technology integration and broaden their market presence. A strategic partnership generally involves a collaborative arrangement among two or more organizations that pools their resources, expertise, and initiatives to pursue shared goals or objectives. For example, in July 2024, Konica Minolta - a Japan-based technology firm - and Picterus AS - a Norway-based medical-technology company - revealed a strategic collaboration to advance non-invasive jaundice screening for newborns. Drawing on Konica Minolta’s expertise in transcutaneous bilirubin measurement via its JM-105 jaundice meter and Picterus’ smartphone-powered Picterus Jaundice Pro solution, the partnership seeks to boost early identification of pathological jaundice, minimize dependence on invasive blood draws, and improve clinical results by averting serious bilirubin-induced issues in infants.

In December 2023, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., a medical device firm based in China, purchased DiaSys Diagnostic Systems GmbH for an undisclosed sum. Through this acquisition, Mindray aims to speed up its supply chain platform development, acquire a talented global workforce, and bolster its in vitro diagnostics portfolio. Mindray also pledges to provide DiaSys with resources and backing, drawing on its deep expertise in worldwide integration to drive mutual synergistic expansion for both entities. DiaSys Diagnostic Systems GmbH, headquartered in Germany, specializes in manufacturing bilirubin meters.

Major companies operating in the bilirubin meters market are Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., PerkinElmer, Drägerwerk AG & Co., Sysmex Corporation, Konica Minolta Business Solutions Inc., Masimo Corp., Beckman Coulter Inc., Nova Biomedical, Ningbo David Medical Device Co. Ltd., Reichert Inc., A. Menarini Diagnostics Srl, Delta Medical International Ltd., AVI Healthcare Pvt Ltd., Olidef, Micro Lab Instruments, Aegis Medical Innovations Inc., Medi Waves Inc., Ginevri Srl.

North America was the largest region in the bilirubin meters market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bilirubin meters market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bilirubin meters market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the bilirubin meters market by increasing costs of imported optical sensors, electronic components, calibration materials, and medical-grade plastics used in device manufacturing. Hospitals and diagnostic centers in North America and Europe are most impacted due to reliance on imported medical devices, while Asia-Pacific faces higher costs for export-oriented production. These tariffs are raising device procurement costs and slowing replacement cycles. However, they are also driving local manufacturing, regional assembly of diagnostic devices, and innovation in cost-efficient bilirubin monitoring solutions.

The bilirubin meters market research report is one of a series of new reports that provides bilirubin meters market statistics, including bilirubin meters industry global market size, regional shares, competitors with a bilirubin meters market share, detailed bilirubin meters market segments, market trends and opportunities, and any further data you may need to thrive in the bilirubin meters industry. This bilirubin meters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A bilirubin meter is a medical device that measures bilirubin concentration in a patient's blood. These devices may be invasive, needing a blood sample, or non-invasive, employing transcutaneous techniques to assess bilirubin levels via the skin. Bilirubin meters play a crucial role in healthcare environments, enabling precise and prompt diagnosis and treatment of conditions linked to liver function and red blood cell degradation.

The primary bilirubin meters consist of transcutaneous devices and benchtop models. Transcutaneous devices are medical instruments intended for use on or through the skin to administer therapeutic substances, track physiological states, or perform medical tasks without requiring invasive methods. They serve both neonates and adults in managing jaundice, hepatitis, and various other conditions. These devices find application in hospitals, medical centers, and similar settings.

The bilirubin meter market consists of sales of serum bilirubin analyzers, phototherapy equipment, disposable bilirubin test strips and neonatal blood collection kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.